n humans, the intake of sugar-sweetened beverages is correlated with the prevalence of type 2 diabetes mellitus and obesity.
(PI3K)-Akt-neuronal NO synthase (nNOS)-NO-mediated signaling in the NTS. 4 Caffeine is most likely the world's most frequently ingested pharmacological substance. Epidemiological studies have shown that long-term caffeine consumption diminishes diabetic symptoms by enhancing insulin sensitivity through more efficient insulin signaling. 11, 12 However, although some studies have shown that acute caffeine consumption elevates BP, other studies have shown that habitual coffee intake is less likely to increase BP. 13, 14 In fact, current studies have suggested a protective role of coffee intake against hypertension. 14, 15 Nevertheless, the relationship between fructose-induced hypertension and caffeine-antagonized hypertension has not been established. Therefore, we tested the hypothesis that caffeine can inhibit fructose-induced hypertension.
In the present study, we examined whether superoxide could be inhibited by administering caffeine. In addition, we investigated the downstream signaling pathway involved in the effect of caffeine on the NTS. Our results suggest that a defect in the insulin receptor substrate 1 (IRS1)-PI3K-Akt-nNOS signaling pathway in the NTS is involved in the superoxide-mediated modulation of hypertension of fructose-fed rats. However, the most interesting finding of this study was that caffeine may reverse the defect in the insulin signaling pathway through reduction of superoxide generation.
Materials and Methods
Additional experimental detail is provided in the online-only Data Supplement.
Results

Consumption of Fructose Induces Metabolic Indicators in Rats
The Table provides the body weight and BP, fasting plasma glucose, insulin, triglyceride, high-density lipoprotein, plasma norepinephrine, and cholesterol levels measured in the experimental groups. As recently reported from a previous study, 16 our results revealed significant elevation of serum triglyceride concentrations in the fructose group compared with the control group. Fasting blood glucose was higher in the fructose group. Furthermore, serum insulin and homeostatic model assessment-insulin resistance index were elevated in fructose-fed rats, whereas direct high-density lipoprotein level was significantly decreased. As shown in the Table, fructose administration significantly increased systolic BP and mean BP compared with the control group. There was no difference in body weight after fructose treatment compared with the control group.
Caffeine Prevents Fructose-Mediated Metabolic Defects
The levels of fasting glucose, insulin, homeostatic model assessment-insulin resistance, norepinephrine, and triglycerides were significantly reduced, whereas direct high-density lipoprotein levels were increased in the fructose-caffeine group compared with the fructose group. These results indicate that caffeine can suppress fructose-induced hypertension.
Caffeine Inhibits Fructose-Induced Impairment of NO Production in the NTS
Interestingly, NO production in the NTS was found to decrease significantly after fructose administration ( Figure 1A , lanes 1 and 2). Caffeine stimulates increased central NO production in the brain. 17 Our findings revealed that treatment with caffeine resulted in the recovery of fructose-induced decrease of NO production in the NTS ( Figure 1A, lanes 2 and 3) . Immunoblotting analysis demonstrated that fructose could significantly decrease nNOS phosphorylation in the NTS ( Figure 1B and 1C, lanes 1 and 2). Furthermore, immunofluorescence staining against phosphorylated nNOS S1416 in the NTS revealed that fructose reduced the number of phosphorylated nNOS S1416 -positive cells compared with the control group ( Figure 1D and 1E, lanes 1 and 2). We performed immunoblotting and immunofluorescence analyses to determine whether caffeine pretreatment could restore nNOS S1416 phosphorylation in the NTS of fructose-fed rats ( Figure 1B-1E , lanes 2 and 3). However, immunofluorescence and immunoblotting analyses showed no significant difference in nNOS S1416 Body weights, levels of serum triglycerides, serum norepinephrine, fasting serum glucose, and fasting serum insulin, systolic blood pressure, mean blood pressure, and dHDL cholesterol levels were determined in fructose-or caffeine-treated rats. 
Caffeine Attenuates Fructose-Induced Insulin Signaling Defects in the NTS
Our previous studies demonstrated that nNOS is a downstream factor of insulin-PI3K-Akt signaling-mediated central BP regulation in the NTS. 18 We further tested whether caffeine might activate the Akt-nNOS cascade in the NTS. Immunoblotting analysis revealed significantly decreased Akt S473 phosphorylation in the NTS of fructose-fed rats compared with controls ( Figure 2A and 2B, lanes 1 and 2). After the administration of caffeine, a significant increase in Akt S473 phosphorylation was observed in the fructose-fed rats ( Figure 2A and 2B, lanes 2 and 3), whereas the level in the caffeine group was unchanged compared with the control group ( Figure 2A and 2B, lanes 1 and 4) .
Previously, we provided evidence that microinjection of insulin in the NTS induces depressor effects in normotensive Wistar-Kyoto rats. 4 To confirm whether caffeine influences the relationship between insulin and BP regulation in the NTS, we microinjected insulin into the NTS and monitored the resultant changes in BP. Microinjection of insulin into the NTS produced prominent depressor effects in controls ( Figure 2C and 2D, lane 1) . Similarly, significant depressor effects were observed in caffeine group rats after insulin injection ( Figure 2C and 2D, lane 4) . The depressor response to insulin was significantly attenuated by fructose administration ( Figure 2C and 2D, lane 2). However, the insulin-induced depressor effect in the NTS was restored after caffeine treatment in the fructose group ( Figure 2C and 2D, lane 3).
We then investigated whether the administration of fructose and caffeine influences the insulin content in the NTS. Figure 3E shows that a significant decrease in the insulin level was observed in comparison with fructose ( Figure 2E , lanes 1 and 2). After treatment with caffeine for 4 weeks, the insulin concentration was reduced significantly in the fructose group ( Figure 2E, lanes 2 and 3) . However, the analysis of insulin level showed no significant differences in the NTS between the control and caffeine groups ( Figure 2E, lanes 1 and 4) .
A recent study indicated that fructose-induced insulin resistance increases the phosphorylation of IRS1 at serine 307. 19 Therefore, we further investigated whether IRS1 S307 phosphorylation participates in the insulin signaling defect induced by fructose in the NTS. The results of the immunoblotting analysis demonstrated that fructose increased IRS1 S307 phosphorylation in the NTS compared with the controls ( Figure 2F and 2G, lanes 1 and 2). As expected, we observed that caffeine inhibited IRS1 S307 phosphorylation in the NTS of the fructose group ( Figure 2F and 2G, lanes 2 and 3) . However, the phosphorylation of IRS1 S307 was not significantly different between the caffeine and control groups ( Figure 2F and 2G, lanes 1 and 4).
Caffeine Inhibits Fructose-Induced Superoxide Generation and Receptor of Advanced Glycation End-Product Expression in the NTS
Previous research has shown that superoxide induces phosphorylation at serine 307 of IRS1. 20 Therefore, we investigated the in situ level of superoxide in the NTS to establish a potential association between fructose and superoxide production. In the present study, the cells in the NTS of the fructose group rats exhibited significantly higher dihydroethidium fluorescence activity compared with control group rats (Figure 3A Caffeine ameliorates the fructose-induced impairment of nitric oxide (NO) production and increased neuronal NO synthase (nNOS) phosphorylation in the nucleus tractus solitarii (NTS). A, Administration of fructose results in low levels of NO. Systemic treatment with caffeine leads to significantly elevate NO levels in the NTS in the fructose group compared with the fructose controls. B, Immunoblots depicting low levels of phosphorylated (P)-nNOS S1416 protein in the NTS of the fructose group compared with the control group (lanes 1 and 2). Caffeine treatment increases the level of P-nNOS S1416 protein in the fructose group (lanes 3). C, The results of densitometric analyses of P-nNOS S1416 levels are shown before and after treatment with fructose or caffeine. D, Representative green fluorescence images of P-nNOS S1416 cells in the NTS before and after systemic administration of fructose or caffeine. The nuclei of the cells in the NTS were counterstained with 4',6-diamidino-2-phenylindole and exhibit blue fluorescence. Note the reduced intensity of green fluorescence observed in the NTS sections in the fructose group compared with other groups. E, The bar graphs are representative of the P-nNOS S1416 fluorescence intensity in the NTS of the indicated groups. Note the significantly greater P-nNOS S1416 fluorescence intensity in the NTS of the fructose-caffeine group. The presented values are mean±SEM (n=6). *P<0.05 vs the control group; #P<0.05 vs the fructose group. and 3B, lanes 1 and 2). However, caffeine treatment reduced fructose-induced dihydroethidium fluorescence activity in the NTS ( Figure 3A and 3B, lanes 2 and 3), whereas no significant difference was observed between caffeine and controls ( Figure 3A and 3B, lanes 1 and 4). We then investigated whether fructose influenced receptor of advanced glycation end product (RAGE) expression in the NTS. The results of the immunofluorescence analysis showed that fructose intake significantly increased RAGE expression in the NTS ( Figure 3C and 3D, lanes 2). Conversely, after caffeine treatment, the fructose-fed rats displayed a significant decrease in RAGE expression compared with the fructose rats ( Figure 3C and 3D, lanes 2 and 3). No change in RAGE expression was observed in the caffeine group rats compared with the control group rats ( Figure 3C and 3D, lanes 1 and 4).
Discussion
Recently, epidemiological reports have suggested that dietary fructose intake promotes hyperlipidemia, hyperinsulinemia, and hypertension. 21, 22 Our findings extend these observations to fructose-fed rats, which show similar metabolic disturbances. 14, 23 In the present study, fructose intake caused increased levels of serum norepinephrine, serum triglycerides, insulin, and fasting serum glucose and reduced high-density lipoprotein but resulted in no change in body weight or cholesterol compared with control rats. However, there is some controversy about fructose-induced hypertension, mainly related to the potential to develop hypertension, and many potential explanations for the discrepancy in these findings have been offered, such as differences in the techniques used to measure BP and the feed or drinking conditions. 3, 24 In particular, most studies have found that administering rats 10% fructose in drinking water induces a more severe metabolic disorder compared with providing 60% fructose in food. 22, 24 In this study, we used 10% fructose in drinking water as a fructose-induced hypertension model. Our data revealed the presence of hypertension in fructose-fed rats.
Previous studies have demonstrated that the development of hypertension is associated with insulin resistance and hyperinsulinemia. 21, 25 Using fructose-fed rats as an animal model of insulin resistance, several studies have revealed increased superoxide generation. 7, 21 Furthermore, hyperinsulinemia could activate the sympathetic nerve system, which in turn will elevate the BP. 26 These observations demonstrate that the existence of a functional sympathetic nervous system is required for the development of elevated BP and plasma insulin levels in fructose-fed rats. 27 Furthermore, in a clinical setting, derangements of the peripheral endothelial NO system have been related to the development of hypertension. 28 It may be a pathogenic factor for abnormal regulation of vascular tones through imbalance of NO and superoxide production, which may be associated with the development of hypertension in the insulin-resistant state. 29 However, Liu et al 23 demonstrated that the vascular NO pathway may not be causally related to the development of fructose-induced hypertension. 28 In a previous study, we showed that angiotensin II induces superoxide generation, which impairs NO production in the NTS. 10 The depressor effect of NO in the NTS occurs through the inhibition of sympathetic nervous activity. 30 Our findings extend previous observations that central insulin resistance in the NTS might participate in a superoxide-dependent pathway via the impairment of NO production to produce hypertension of fructose-fed rats.
High-fructose diets increase the phosphorylation of serine 307 on IRS1 in rats. 19 Increased serine phosphorylation on IRS1 decreases the association of IRS1 with the insulin receptor and inhibits PI3K activity, thereby inhibiting insulin protein levels before and after treatment with fructose or caffeine. C, Representative tracings demonstrating the cardiovascular effects of insulin in the unilateral NTS of anesthetized rats. The depressor effects of insulin are significantly attenuated by fructose administration. After caffeine treatment in the fructose group, the depressor effects of insulin are recovered. D, Summarized data are shown in the graph, revealing the effects on mean blood pressure (MBP) after the microinjection of insulin into unilateral NTS. E, Fructose treatment results in high levels of insulin, whereas systemic treatment with caffeine leads to significantly decreased insulin levels in the NTS in the fructose group compared with fructose controls. F, Immunoblots depicting low levels of P-insulin receptor substrate 1 (IRS1) S307 protein in the NTS in the fructose group compared with the control group (lanes 1 and 2). Caffeine treatment increases the level of P-IRS1 S307 protein in the fructose group (lane 3). G, Densitometric analysis of P-IRS1 S307 protein levels before and after treatment with fructose or caffeine. The values indicated with bars are mean±SEM (n=6). *P<0.05 vs control and #P<0.05 vs fructose.
by guest on June 22, 2017 http://hyper.ahajournals.org/ Downloaded from signaling. 31 In addition, our previous findings showed that insulin-PI3K-Akt-nNOS signaling in the NTS is linked to NO production and BP regulation. 18 The present study provides further support for these observations by showing that the IRS1-PI3K-Akt-nNOS signaling defect in the NTS is involved in fructose-associated hypertension. Furthermore, the dietary fructose-mediated generation of advanced glycation end products and activation of RAGE contribute to metabolic syndrome. 32 In particular, most studies have found that the increased generation of RAGE in the brains of fructose-fed rats may contribute to the impairment of insulin resistance in the brain. 23, 33 However, activation of nicotinamide adenine dinucleotide phosphate oxidase by advanced glycation end product-mediated superoxide generation led to altered gene expression via RAGE. 34 Nicotinamide adenine dinucleotide phosphate oxidase was a major source of superoxide generation because its activation was associated with impaired bioavailability of NO. 34 The findings of this study are further supported by reports that RAGE-mediated nicotinamide adenine dinucleotide phosphate oxidase activation may participate in the regulation of central insulin resistance by fructose in rats. Nevertheless, in the present study, we also observed that caffeine may inhibit fructose-induced superoxide generation caused by RAGE-mediated nicotinamide adenine dinucleotide phosphate oxidase activation.
Fructose consumption is known to influence adenine nucleotide catabolism and ATP at the cellular level. 35 However, caffeine is a known competitive antagonist of adenosine receptors. 36 Our previous findings demonstrated that the adenosine A2a-extracellular signal-regulated protein kinase 1/2-endothelial NOS signaling pathway in the NTS mediates NO production associated with the regulation of BP. 37 Interestingly, long-term caffeine consumption diminishes diabetic symptoms by enhancing insulin sensitivity through more efficient insulin signaling. 12 In the present study, we also observed that caffeine may alleviate fructose-induced metabolic disturbances. However, some researchers have concluded that caffeine consumption may elevate BP, leading to a higher risk of hypertension. 38, 39 Conversely, most epidemiological studies have shown that the habitual intake of caffeinated coffee does not increase the risk of hypertension, 15, 38 and chronic caffeine intake has been found to prevent diet-induced hypertension. 14 Corti et al 13 also demonstrated that in habitual coffee drinkers, there is no significant change in systolic BP after coffee consumption. The results of the present study suggested that caffeine treatment does not induce hypertension. Interestingly, caffeine treatment was able to abolish fructose-induced hypertension. Furthermore, our data showed that the A2a-extracellular signal-regulated protein kinase 1/2-endothelial NOS pathway may not participate in the regulation of central BP by caffeine or fructose in rats. Thus, we speculate that caffeine intake may abolish the hypertension induced by fructose through other mechanisms. However, further studies are needed to verify this signaling mechanism in the NTS.
Several studies have suggested regulatory roles of caffeine associated with its biological effects. First, caffeine has been demonstrated to stimulate increased central NO production in the brains of mice. 17 Second, because caffeine is an antioxidant, regular caffeine intake prevents diet-induced insulin resistance. 14 Third, caffeine can activate Akt phosphorylation. 11, 12, 14 Fourth, caffeine intake did not affect circulating insulin secretion significantly. 40 Finally, caffeine does not alter the phosphorylation of the insulin receptor, IRS1-associated PI3K, or Akt S473 . 41 These findings suggest the possibility of a broad physiological role for caffeine. In the present study, we observed that caffeine could improve insulin sensitivity and decrease insulin level in the NTS of fructose-fed rats. However, the mechanism through which caffeine enhances insulin sensitivity is not clear. Our current findings provide further support for these observations by showing that caffeine may upregulate IRS1-PI3K-Akt-nNOS signaling. We also observed that caffeine stimulates NO production in the NTS to reduce fructose-induced hypertension. Taken together, these results suggest that caffeine may reverse the defect in the insulin signaling pathway to increase NO production in the NTS. However, the mechanism connecting caffeine and insulin signaling in the NTS remains unknown. Further studies are needed to verify the downstream pathways that mediate the effect of caffeine in enhancing insulin sensitivity and the prevention of hypertension.
In conclusion, we have suggested in this report that caffeine may enhance insulin sensitivity in the NTS to prevent fructose-induced hypertension by increasing NO production. Furthermore, we showed that caffeine may upregulate IRS1-PI3K-Akt-nNOS signaling via reduced superoxide generation to enhance NO production in the NTS. This is the first study to demonstrate the mechanism through which caffeine may increase insulin sensitivity in the NTS and reduce high BP.
Perspectives
Both insulin resistance and superoxide generation have been identified as underlying pathogenic mechanisms associated with hypertension. In this study, we demonstrated the importance of fructose and caffeine in the NTS in mediating superoxide-associated central insulin resistance. We also investigated the cross talk between caffeine and fructose in the pathogenesis of hypertension. Whether this interplay between the systemic administration of fructose and caffeine takes place in other areas of the brain involved in the maintenance of central cardiovascular regulation also warrants investigation. Much more work will be necessary to understand the role of caffeine in hypertension for potential applications in therapeutic strategies. 
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ONLINE SUPPLEMENT
Radio-Telemetry Monitoring of Blood Pressure 29
The Dataquest IV telemetry system (Data Sciences International, New Brighton, 30
Minnesota) was used for the measurement of systolic pressure, diastolic pressure, mean 31 arterial pressure, and heart rate, as previously described. 1 The monitoring system consists of a 32 transmitter (a radio frequency transducer model TA11PA), receiver panel, consolidation 33 matrix, and personal computer with accompanying software. Before the device was 34 implanted, calibrations were verified for accuracy within 63 mmHg. Rats at 8 weeks of age 35
were anesthetized with Zoletil 50. The flexible catheter of the transmitter was surgically 36 secured in the abdominal aorta just below the renal arteries and pointed upstream (against the 37 flow), and the transmitter was sutured to the abdominal wall. The rats were housed in 38 3 individual cages following the operation. For data acquisition, each cage was placed over a 1 receiver panel, which was connected to the personal computer.
2
The experimental rats were unrestrained and free to move within their cages. 3
Hemodynamic data were sampled every 5 minutes for 10 seconds. Preliminary experiments 4
showed that the blood pressure and heart rate of the rats stabilized 7 days after the operation. 5
Therefore, each drug treatment was commenced 7 days after surgery, and telemetry data were 6 collected for 28 days of treatment. 7
8
Immunoblotting Analysis 9
The NTS was dissected via micropunch (1 mm inner diameter) from a 1 mm-thick 10 brainstem slice at the level of the obex under a microscope. Briefly, total protein was 11 prepared by homogenizing the NTS for 1 hour at 4°C in lysis buffer, a protease inhibitor 12 cocktail, and phosphatase inhibitor cocktail 2 (all purchased from Sigma-Aldrich). Protein 13 extracts (20 µg/sample assessed through a BCA protein assay, Pierce Chemical Co., IL, USA) 14 were subjected to 6-12.5% SDS-Tris glycine gel electrophoresis and transferred to a 15 polyvinylidene fluoride membrane (GE Healthcare, Buckinghamshire, UK). The membranes 16
were blocked and incubated at 4°C overnight with the appropriate antibody: anti-P-IRS1 S307 , 17
anti-IRS1 (Millipore, Billerica, MA, USA); anti-P-Akt S473 , anti-Akt (Cell Signaling  18 Technology, Danvers, MA, USA); anti-P-nNOS S1416 (Abcam, Cambridge, UK); anti-nNOS 19 (Millipore, Billerica, MA, USA); or anti-RAGE (Santa Cruz Biotechnology, Santa Cruz, CA, 20 USA).
22
In Situ Detection of Superoxide in the NTS 23 Endogenous in vivo superoxide production in the NTS was determined via 24 dihydroethidium (DHE; Invitrogen, Carlsbad, CA, USA) staining. The NTS was dissected, 25 quickly frozen, embedded in OCT, and then placed in liquid nitrogen. Cryostat slices (30 µm) 26 were stained in the dark for 30 min at 37°C with 1 µM DHE. The samples were analyzed 27 using confocal microscopy (Carl Zeiss LSM 5 PASCAL, Göttingen, Germany). 28 29
Measurement of NO in the NTS 30
Samples were deproteinized with Microcon YM-30 centrifugal filter units (Millipore).
31
The amount of total NO in the samples was determined using a modified protocol based on 32 the purge system of the Sievers Nitric Oxide Analyzer (NOA 280i; Sievers Instruments, 33
Boulder, CO, USA) involving chemiluminescence. The samples (5 µl) were injected into a 34 reflux column containing 0.1 mol/L VCl 3 in 1 mol/L HCl at 90°C to reduce any nitrates or 35 nitrites (NOx) to NO. NO was then combined with the O 3 produced by the analyzer to form 36 NO 2 . The resulting emissions from the excited NO 2 were detected by a photomultiplier tube 37 and recorded digitally (mV). The values were then plotted on a standard curve of NaNO 3 38 4 concentrations determined simultaneously. Measurements were collected in triplicate for each 1 sample.
3
Measurement of Insulin in the NTS 4 NTS insulin levels were measured using the Ultrasensitive Rat Insulin ELISA kit 5 (Mercodia, Uppsala, Sweden) and detected using the Biochrom Anthos Zenyth 200rt 6
Microplate Reader (Cambridge, UK). 7 8
Intra-NTS Microinjection 9
The preparation of animals for intra-NTS microinjection and the methods used to locate 10 the NTS have been described previously 2 . Briefly, a polyethylene cannula was inserted into 11 the femoral vein for fluid supplementation. Blood pressure (BP) was measured via a femoral 12 artery cannula with a pressure transducer and polygraph (Gould, Cleveland, OH, USA). 
Caffeine May Not Influence A2a-ERK1/2-eNOS Signaling in the NTS 21
It has been reported that caffeine is an antagonist of all subtypes of adenosine receptors. 3 In a  22 previous study, we demonstrated that adenosine A2a-ERK1/2-eNOS signaling in the NTS 23 promotes NO production, which is associated with the regulation of BP. 3 Therefore, we 24 determined whether caffeine influences A2a-ERK1/2-eNOS signaling in the NTS. However, 25
immunoblotting analyses revealed no significant changes in the levels of the A1 receptor and 26
A2a receptor in the NTS of all groups. The levels of ERK1/2 T202/Y204 and eNOS S1177 27 phosphorylation also showed no significant differences following caffeine treatment ( Figure  28 S2). 29
30
Caffeine Inhibits Fructose-Induced NADPH Oxidase Activity in the NTS 31 Figure S3 shows that NADPH oxidase activity was significantly higher in NTS from fructose 32 fed rats compared with control group rats, and treatment with caffeine significantly prevented 33 the increase in NADPH oxidase activity. Immunoblotting analysis revealed significantly 34 increased gp91 protein levels in the NTS of fructose-fed rats compared to the controls 35 ( Figures S4A and S4B, lanes 1 and 2) . Following the administration of caffeine, a significant 36 6 increase in gp91 protein levels was observed in the fructose-fed rats ( Figures S4A and S4B,  1  lanes 2 and 3) , whereas the level in the caffeine group was unchanged compared to the 2 control ( Figures S4A and S4B, lanes 1 and 4) . The results of the immunoblotting analysis 3 demonstrated that fructose increased P67 protein levels in the NTS compared to the controls 4 ( Figures S4C and S4D, lanes 1 and 2) . As expected, we observed that caffeine inhibited P67 5 protein levels in the NTS of the fructose group ( Figures S4C and S4D, lanes 2 and 3) . 6
However, the P67 protein levels were not significantly different between the caffeine and 7 control groups ( Figures S4C and S4D, lanes 1 and 4) . Immunoblotting analysis demonstrated 8 that fructose could significantly increase P22 protein levels in the NTS ( Figures S4E and S4F , 9 lanes 1 and 2). .Caffeine pretreatment could attenuate P22 protein levels in the NTS of 10 fructose-fed rats ( Figures S4E and S4F, lanes 2 and 3) . However, no significant difference in 11 P22 protein levels between the caffeine group and the control group ( Figures S4E and S4F , 12 lanes 1 and 4). However, immunoblotting analyses revealed no significant changes in the 13 levels of the P47 protein levels in the NTS of all groups ( Figure S4G and S4H). 14 15 Immunoblots revealing that the same levels of Adenosine 1 receptor (A1R) protein are 6 present in the NTS in the fructose group and in the control group (lanes 1 and 2). Caffeine 7 treatment results in no change in the level of A1R protein in the fructose group (lane 3). B, 8 The results of densitometric analyses of A1R levels are shown before and after treatment with 9 fructose or caffeine. The values indicated with bars are the mean±SEM (n=6). C, 10
Immunoblots revealing that the same levels of Adenosine 2 receptor (A2R) protein are 11 present in the NTS in the fructose group and in the control group (lanes 1 and 2 
